Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by-nc-nd (c) Wieduwilt, Matthew J. et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183782

Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLAmatched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P <_ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P <_ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (<_18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Citació

Citació

WIEDUWILT, Matthew j., METHENY, Leland, ZHANG, Mei-jie, WANG, Hai-lin, ESTRADA MERLY, Noel, MARKS, David i., AL-HOMSI, A. samer, MUFFLY, Lori, CHAO, Nelson j., RIZZIERI, David, GALE, Robert peter, GADALLA, Shahinaz m., CAIRO, Mitchell s., MUSSETTI, Alberto, GORE, Steven d., BHATT, Vijaya raj, PATEL, Sagar s., MICHELIS, Fotios v., INAMOTO, Yoshihiro, BADAWY, Sherif m., COPELAN, Edward, PALMISIANO, Neil, KHARFAN DABAJA, Mohamed a., LAZARUS, Hillard m., GANGULY, Siddhartha, BREDESON, Christopher n., DIAZ PEREZ, Miguel angel, CASSADAY, Ryan, SAVANI, Bipin n., KUHN BALLEN, Karen, MARTINO, Rodrigo, WIRK, Baldeep, BACHER, Ulrike, ALJURF, Mahmoud, BASHEY, Asad, MURTHY, Hemant s., YARED, Jean a., ALDOSS, Ibrahim, FARHADFAR, Nosha, LIU, Hongtao, ABDEL AZIM, Hisham, WALLER, Edmund k., SOLH, Melhem, SEFTEL, Matthew, VAN DER POEL, Marjolein w.m., GRUNWALD, Michael richard, LIESVELD, Jane l., KAMBLE, Rammurti t., MCGUIRK, Joseph p., MUNKER, Reinhold, CAHN, Jean-yves, WOOK LEE, Jong, FREYTES, Cesar o., KREM, Maxwell, WINESTONE, Lena e., GERGIS, Usama, NATHAN, Sunita, OLSSON, Richard f., VERDONCK, Leo f., SHARMA, Akshay, RINGDEN, Olle, FRIEND, Brian d., CERNY, Jan, CHOE, Hannah k., CHHABRA, Saurabh, NISHIHORI, Taiga, SEO, Sachiko, GEORGE, Biju, BAXTER LOWE, Lee ann, HILDEBRANDT, Gerhard c., LIMA, Marcos de, LITZOW, Mark r., KEBRIAEI, Partow, HOURIGAN, Christopher s., BILAL ABID, Muhammad, WEISDORF, Daniel j., SABER, Wael. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. _Blood Advances_. 2021. Vol. 6, núm. 1, pàgs. 339-357. [consulta: 26 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/183782]

Exportar metadades

JSON - METS

Compartir registre